Form 8-K Travere Therapeutics, For: Feb 20
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Wall St futures rise as AI stocks rally, crude prices fall
- Oil prices slide to 11-day low on hopes of US-Iran diplomacy, Saudi exports
- Warren Buffett transitions to Berkshire’s chairman emeritus
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Qatar Investment Authority targets $20B partnership with JPMorgan - Bloomberg
- Streamflation drives 39% of Americans to cancel streaming in 6 months
Travere Therapeutics (TVTX) PT Raised to $35 at Citi
February 24, 2025 4:58 AM ESTCiti analyst Carly Kenselaar raised the price target on Travere Therapeutics (NASDAQ: TVTX) to $35.00 (from $31.00) while maintaining a Buy rating.
The analyst comments "We anticipate continued growth for FILSPARI in 2025, driven by 1) expected approval in FSGS in 4Q25 with an sNDA... More
